日报更新时间：
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：中大制药
英文名称：Conatus Pharmaceuticals
简介：Conatus Pharmaceuticals Inc.于2005年7月13日在特拉华州注册成立
电话：1-858-3762600
Conatus Pharmaceuticals是一家生物技术公司，专注于治疗肝病的新药的开发和商业化。Conatus Pharmaceuticals的主要化合物产品Emricasan是一种一流的口服活性泛半胱天冬酶蛋白酶抑制剂，旨在降低人类半胱天冬酶的活性，这是一种介导炎症和细胞凋亡的酶。公司相信通过降低这些酶的活性，emricasan有可能阻断肝脏疾病的进展，并可能在肝脏疾病的多个领域提供治疗选择。目前处于原位肝移植后丙型肝炎病毒感染的 IIb 期临床试验中。Conatus Pharmaceuticals观察到令人信服的临床前和临床试验结果表明，无论原始疾病的原因如何，emricasan可能在减缓肝脏疾病进展方面具有临床效用。迄今为止，emricasan已在16项临床试验中对650多名受试者进行了研究，这些临床试验涉及广泛的肝病病因和进展阶段。在多项临床试验中，emricasan已显示出与肝病严重程度和进展有关的炎症和细胞凋亡关键生物标志物水平的统计学显着，一致，快速和持续的降低。重要的是，已知这些关键生物标志物在目前正在追求的多种肝脏适应症中升高并具有预后价值。2016年12月，Conatus宣布与诺华公司就emricasan的全球发展和商业化达成独家选择、合作和许可协议。2017年5月，Conatus宣布诺华公司在开始进行 IIb 期ENCORE-LF临床试验后已行使其许可选项。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2018-11-13 | Ripley (Daniel L.) | Officer | Buy | 1861 | 3.15 |
| 2018-11-13 | Smith Edward F Iii | Officer | Buy | 1724 | 3.15 |
| 2018-05-13 | Ripley (Daniel L.) | Officer | Buy | 1290 | 3.31 |
| 2018-05-13 | Smith Edward F Iii | Officer | Buy | 4690 | 3.31 |
| 2018-05-03 | Mento (Steven J) | Chief Executive Officer | Buy | 60000 | 0.99 |
| 2018-02-26 | Spada (Alfred P) | Officer | Buy | 12121 | 1.24 |
| 2017-11-13 | Ripley (Daniel L.) | Officer | Buy | 818 | 3.48 |
| 2017-11-13 | Smith Edward F Iii | Officer | Buy | 4461 | 3.48 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| D. E. Shaw & Co LP | 87667 | 0.26% | 25504 | 41.03% | 2019-03-31 |
| Geode Capital Management, LLC | 239083 | 0.72% | -177609 | -42.62% | 2019-03-31 |
| Acadian Asset Management LLC | 245078 | 0.74% | 245078 | -- | 2019-03-31 |
| Parallax Volatility Advisers, LLC | 329751 | 0.99% | 226571 | 219.59% | 2019-03-31 |
| BlackRock Fund Advisors | 872939 | 2.63% | -65395 | -6.97% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 1274567 | 3.84% | -- | -- | 2019-07-31 |
| BlackRock Inc | 1562521 | 4.71% | -49531 | -3.07% | 2019-03-31 |
| Vanguard Group Inc | 1638895 | 4.94% | 1050759 | 178.66% | 2019-03-31 |
| Mpm Asset Management, LLC | 2464807 | 7.43% | -- | -- | 2019-03-31 |
| Fidelity Management & Research Company | 226082 | 0.68% | -84437 | -27.19% | 2019-07-31 |
| BlackRock Advisors LLC | 225141 | 0.68% | -- | -- | 2019-07-31 |
| Hikari Power Ltd | 200488 | 0.60% | 33200 | 19.85% | 2019-03-31 |
| Bank of America Corporation | 92104 | 0.28% | -179 | -0.19% | 2019-03-31 |
| QS Investors LLC | 96807 | 0.29% | -- | -- | 2019-03-31 |
| Vassalluzzo Scott J | 124643 | 0.38% | 20200 | 19.34% | 2019-03-31 |
| Susquehanna International Group, LLP | 130379 | 0.39% | 8504 | 6.98% | 2019-03-31 |
| Susquehanna Financial Group, LLLP | 130379 | 0.39% | 8504 | 6.98% | 2019-03-31 |
| Vanguard | 158105 | 0.48% | -- | -- | 2019-07-31 |
| United Capital Financial Advisers Inc | 175476 | 0.53% | -63 | -0.04% | 2019-03-31 |
| Bridgeway Capital Management, Inc | 183300 | 0.55% | 80000 | 77.44% | 2019-03-31 |
| Mellon Investments Corporation | 137500 | 0.41% | -- | -- | 2018-12-31 |
| Bank of New York Mellon Corp | 160069 | 0.48% | -1380 | -0.85% | 2018-12-31 |
| BOOTHBAY FUND MANAGEMENT, LLC | 189255 | 0.57% | 189255 | -- | 2018-12-31 |
| Sofinnova Ventures | 638197 | 1.92% | 99282 | 18.42% | 2018-12-31 |
| Group One Trading, LP | 217600 | 0.66% | -22328 | -9.31% | 2018-12-31 |
| Two Sigma Investments LLC | 250085 | 0.75% | 221044 | 761.14% | 2018-12-31 |
| BlackRock Institutional Trust Company NA | 121281 | 0.37% | 121281 | -- | 2019-03-31 |
| Artal Group S A | 500000 | 1.51% | 500000 | -- | 2018-09-30 |
| AXA SA | 443624 | 1.34% | -- | -- | 2018-09-30 |
| Courage Capital Management, LLC | 150050 | 0.45% | -92950 | -38.25% | 2018-09-30 |
| BNY Mellon Asset Management North America Corporation | 137500 | 0.41% | -- | -- | 2018-09-30 |
| AXA Investment Managers UK Ltd | 443624 | 1.34% | -- | -- | 2018-12-31 |
| AQR Capital Management LLC | 178093 | 0.59% | -18071 | -9.21% | 2018-11-30 |
| Charles Schwab Investment Management Inc | 180556 | 0.60% | -- | -- | 2018-11-30 |
| Crestline Management LP | 252723 | 0.84% | 252723 | -- | 2018-06-30 |
| Goldman Sachs Group Inc | 418995 | 1.38% | 331475 | 378.74% | 2018-06-30 |
| AllianceBernstein L.P. | 443624 | 1.47% | -- | -- | 2018-09-30 |
| Millennium Management LLC | 369124 | 1.22% | 11445 | 3.20% | 2018-06-30 |
| Goldman, Sachs & Co. | 407896 | 1.35% | 320376 | 366.06% | 2018-06-30 |
| Panagora Asset Management Inc | 133411 | 0.44% | -19564 | -12.79% | 2018-03-31 |
| Alambic Investment Management, L.P. | 264665 | 0.88% | 178461 | 207.02% | 2018-06-30 |
| Merrill Lynch & Co Inc | 139880 | 0.46% | 62552 | 80.89% | 2018-06-30 |
| Mellon Capital Management Corporation | 137500 | 0.46% | -13750 | -9.09% | 2018-06-30 |
| Sunrise Partners LLC | 127799 | 0.42% | 127799 | -- | 2018-06-30 |
| Element Capital Management LLC | 125749 | 0.42% | 125749 | -- | 2018-06-30 |
| BlueCrest Capital Management Ltd. | 97184 | 0.32% | 97184 | -- | 2018-06-30 |
| Morgan Stanley & Co Inc | 78339 | 0.26% | 21254 | 37.23% | 2018-06-30 |
| Oxford Asset Management, LLC | 56669 | 0.19% | -51698 | -47.71% | 2018-03-31 |
| Springbok Capital Management, LLC | 55008 | 0.18% | 55008 | -- | 2018-03-31 |
| Arrowstreet Capital Limited Partnership | 124064 | 0.41% | -17636 | -12.45% | 2018-03-31 |
| Morgan Stanley Smith Barney LLC | 82976 | 0.28% | 31902 | 62.46% | 2018-03-31 |
| TIAA-CREF Investment Management LLC | 141812 | 0.47% | -74954 | -34.58% | 2018-03-31 |
| Northern Trust Investments N A | 294617 | 0.98% | 9216 | 3.23% | 2018-03-31 |
| MPM BioVentures IV QP LP | 2464807 | 9.42% | 2464807 | -- | 2017-05-11 |
| AllianceBernstein LP | 448779 | 1.49% | -4138 | -0.91% | 2018-03-31 |
| State Street Corp | 411838 | 1.37% | 9424 | 2.34% | 2018-03-31 |
| American Century Inv Mgt Inc | 109571 | 0.36% | 109571 | -- | 2018-03-31 |
| Invesco Advisers, Inc | 152890 | 0.51% | 152890 | -- | 2017-12-31 |
| Sterling Capital Management LLC | 129011 | 0.43% | 129011 | -- | 2017-09-30 |
| Numeric Investors LLC | 260451 | 0.87% | -20847 | -7.41% | 2017-09-30 |
| Bogle Investment Management L P | 174512 | 0.58% | -301090 | -63.31% | 2017-09-30 |
| MPM BioVentures IV LLC | 612149 | 2.34% | 16110 | 2.70% | 2016-12-31 |
| MPM BioVentures V LLC | 612151 | 2.34% | 16110 | 2.70% | 2016-12-31 |
| Polar Capital LLP | 156531 | 0.62% | -- | -- | 2016-09-30 |
| KCG AMERICAS LLC | 67748 | 0.27% | 67748 | -- | 2016-09-30 |
| Renaissance Technologies Corp | 62600 | 0.25% | 62600 | -- | 2016-09-30 |
| Credit Suisse First Boston (CSFB) | 39018 | 0.15% | 39018 | -- | 2016-09-30 |
| Reilly Financial Advisors, LLC | 32011 | 0.13% | -- | -- | 2016-09-30 |
| Wedbush Morgan Securities Inc | 28500 | 0.11% | 10500 | 58.33% | 2016-09-30 |
| FNY Managed Accounts LLC | 27000 | 0.11% | 27000 | -- | 2016-09-30 |
| Louis Lacasse | 809887 | 4.00% | 5110387 | -- | 1999-11-30 |
| Entities affiliated with HealthCor Management, L.P. | 1001458 | 4.00% | 6319200 | 0.10% | 1999-11-30 |
| James Scopa | 1192080 | 4.00% | 7522025 | 0.10% | 1999-11-30 |
| Shahzad Malik, M.D. | 2166836 | 4.00% | 13672735 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| BlackRock Extended Equity Market | 56951 | 0.17% | -78 | -0.14% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1274567 | 3.84% | -- | -- | 2019-06-30 |
| Vanguard Extended Market Index Fund | 362868 | 1.09% | -- | -- | 2019-06-30 |
| Bridgeway Ultra Small Company Market Fd | 160000 | 0.48% | 80000 | 100.00% | 2019-03-31 |
| Vanguard VIF Small Co Gr Portfolio | 152005 | 0.46% | -- | -- | 2019-03-31 |
| BlackRock Advantage Small Cap Core Fund | 115372 | 0.35% | -- | -- | 2019-06-30 |
| BlackRock Advantage Small Cap Growth Fd | 109769 | 0.33% | -- | -- | 2019-06-30 |
| BlackRock US SmCp Eq BigData Strat MF | 72288 | 0.22% | 72288 | -- | 2019-03-20 |
| Vanguard Instl Total Stock Market Idx Fd | 33608 | 0.10% | -- | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 27140 | 0.08% | -- | -- | 2019-06-30 |
| State Street U.S. Extended Market Index | 15800 | 0.05% | -- | -- | 2019-06-30 |
| NT Ext Equity Mkt Fd - DC - NL | 19419 | 0.06% | 1413 | 7.85% | 2019-06-30 |
| VALIC Company I Small Cap Fund | 19500 | 0.06% | -- | -- | 2019-05-31 |
| MIP Active Stock Master Portfolio | 21164 | 0.06% | -- | -- | 2019-06-30 |
| NT Ext Equity Market Index Fund - L | 24347 | 0.07% | -- | -- | 2019-06-30 |
| Vanguard Balanced Index Fund | 26615 | 0.08% | -- | -- | 2019-06-30 |
| Fidelity | 26802 | 0.08% | -- | -- | 2019-06-30 |
| Wells Fargo Factor Enhanced Sm Cp IdxCIT | 13369 | 0.04% | -19763 | -59.65% | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | 20798 | 0.06% | 20083 | 2808.81% | 2019-03-31 |
| Wells Fargo Factor Enhanced Small Cap | 21054 | 0.06% | -- | -- | 2019-05-31 |
| QS US Small Capitalization Equity CIF | 74481 | 0.22% | -- | -- | 2019-03-31 |
| QS US Small Capitalization Equity Fund | 21766 | 0.07% | -- | -- | 2019-03-31 |
| iShares Micro-Cap ETF | 72799 | 0.22% | -- | -- | 2019-06-27 |
| BNYM Mellon SL Mkt Completion Fd | 20798 | 0.06% | 20083 | 2808.81% | 2019-03-31 |
| BSF Americas Diversified Eq Abs Ret Fd | 121281 | 0.37% | 121281 | -- | 2018-12-31 |
| Diamond Flexible | 15811 | 0.05% | -34889 | -68.81% | 2019-01-31 |
| SPDR | 17236 | 0.05% | -286 | -1.63% | 2019-03-29 |
| MEDICAL BioHealth | 58181 | 0.18% | -- | -- | 2018-11-30 |
| iShares Russell 2000 Growth ETF | 259489 | 0.78% | 448 | 0.17% | 2018-06-21 |
| iShares Russell 3000 ETF | 16280 | 0.05% | -- | -- | 2018-06-21 |
| FCP MEDICAL BioHealth-Trends | 58181 | 0.18% | -- | -- | 2018-10-31 |
| APO Medical Opportunities | 30273 | 0.09% | -17000 | -35.96% | 2018-11-30 |
| OMI IM GBP AXA Framlington Biotech | 443624 | 1.34% | -- | -- | 2018-11-30 |
| Schwab Small-Cap Equity Fund | 136356 | 0.45% | -- | -- | 2018-03-31 |
| AQR Small Cap Multi-Style Fund | 129965 | 0.43% | -16052 | -10.99% | 2018-03-31 |
| Hartford Small Cap Value Fund | 46979 | 0.16% | -- | -- | 2018-03-31 |
| AXA 2000 Managed Volatility Portfolio | 38752 | 0.13% | -- | -- | 2018-05-31 |
| AQR Small Cap Momentum Style Fund | 37639 | 0.12% | -- | -- | 2018-03-31 |
| American Century Small Company Fund | 59586 | 0.20% | 59586 | -- | 2018-03-31 |
| FCP MEDICAL BioHealth | 58181 | 0.19% | -- | -- | 2018-06-30 |
| Sterling Capital Behav Sm Cp Val Eq Fd | 128033 | 0.42% | -- | -- | 2017-11-30 |
| BNY Mellon EB DL Mkt Completion | 20837 | 0.07% | -- | -- | 2018-06-30 |
| Vanguard Balanced Index Inv | 21492 | 0.07% | -- | -- | 2018-07-31 |
| VALIC Company I Small Cap | 19500 | 0.06% | -- | -- | 2018-07-31 |
| QS Batterymarch US Sm Cap Eq I | 21766 | 0.06% | -- | -- | 2018-06-30 |
| MIP Active Stock Master | 28034 | 0.09% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 36543 | 0.12% | -- | -- | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 39393 | 0.13% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 765014 | 2.54% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 367168 | 1.22% | -- | -- | 2018-07-31 |
| Vanguard VIF Small Co Gr | 152005 | 0.50% | -- | -- | 2018-06-30 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 110100 | 0.37% | 110100 | -- | 2017-06-30 |
| BlackRock Small Cap Growth Eq Instl | 151991 | 0.50% | -1411 | -0.92% | 2018-07-31 |
| Bridgeway Ultra-Small Company Market | 113000 | 0.37% | -- | -- | 2018-06-30 |
| BlackRock Disciplined Small Cp Cor Inv A | 88198 | 0.29% | -- | -- | 2018-07-31 |
| iShares Micro-Cap | 71400 | 0.19% | -- | -- | 2018-09-12 |
| BlackRock Extended Equity Market K | 56564 | 0.19% | 1538 | 2.80% | 2018-06-30 |
| Fidelity VIP Discp Small Cap Inv | 30448 | 0.10% | -6856 | -18.38% | 2018-03-31 |
| Invesco All Cap Market Neutral A | 21900 | 0.07% | -26700 | -54.94% | 2018-03-31 |
| TIAA-CREF Small-Cap Blend Idx Inst | 30219 | 0.10% | -- | -- | 2018-05-31 |
| CREF Stock R1 | 51360 | 0.17% | -71800 | -58.30% | 2018-04-30 |
| LVIP SSgA Small Cap Index Std | 19000 | 0.06% | -- | -- | 2018-03-31 |
| AXA 2000 Managed Volatility K | 38752 | 0.13% | -- | -- | 2018-05-31 |
| AQR Small Cap Momentum Style I | 37639 | 0.13% | -- | -- | 2018-03-31 |
| AQR Small Cap Multi-Style N | 129965 | 0.43% | -16052 | -10.99% | 2018-03-31 |
| Schwab Small-Cap Equity | 136356 | 0.45% | -- | -- | 2018-03-31 |
| American Century Small Company Inv | 59586 | 0.20% | 59586 | -- | 2018-03-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 65123 | 0.22% | 477 | 0.74% | 2018-05-31 |
| American Century NT Small Company Instl | 35768 | 0.12% | 35768 | -- | 2018-03-31 |
| Schwab Small Cap Index | 44200 | 0.15% | -- | -- | 2018-05-31 |
| The Vanguard Russell 2000 Growth Index | 43564 | 0.14% | 2695 | 6.59% | 2018-05-31 |
| BlackRock Russell 2500 | 32751 | 0.11% | -1216 | -3.58% | 2018-03-31 |
| BlackRock Russell 2000 | 38526 | 0.13% | 364 | 0.95% | 2018-03-31 |
| iShares Russell 2000 Growth | 259489 | 1.00% | 448 | 0.17% | 2018-06-21 |
| Hartford Small Cap Core A | 46979 | 0.16% | -- | -- | 2018-03-31 |
| Sterling Capital Behav Sm Cp Val Eq Intl | 128033 | 0.43% | -- | -- | 2017-11-30 |
| Wilshire Micro-Cap ETF | 6452 | 0.03% | -- | -- | 2017-02-08 |
| The Vanguard Total Stock Market Index | 6100 | 0.02% | -- | -- | 2016-12-31 |
| iShares Core S&P Total US Stock Mkt | 4382 | 0.02% | -- | -- | 2017-02-07 |
| AXA/Lord Abbett Micro Cap K | 2650 | 0.01% | -- | -- | 2016-11-30 |
| BNY Mellon Market Completion Fund UC1 | 626 | -- | 12 | 1.95% | 2016-12-31 |
| BlackRock LifePath | 35 | -- | 12 | 52.17% | 2016-03-31 |
| Weiss Alternative Balanced Risk I | 6 | -- | 6 | -- | 2016-12-31 |
| Putnam Global Health Care Fund | 171528 | 0.90% | -- | -- | 2015-09-30 |
| Polar Capital Glb Healthcare Gr & Inc | 156531 | 0.80% | -- | -- | 2015-09-30 |
| Bridgeway Ultra Small Company Market | 65000 | 0.30% | -- | -- | 2015-09-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 52030 | 0.30% | -- | -- | 2015-09-30 |
| Prudential Jennison Health Sciences | 522993 | 2.60% | -- | -- | 2015-09-30 |
| Putnam VT Global Health Care | 18999 | 0.10% | -- | -- | 2015-09-30 |
| BlackRock Health Sciences | 8200 | -- | -- | -- | 2015-06-30 |
| Mellon Capital EB DL Mkt Completion Fund | 7186 | -- | -- | -- | 2015-09-30 |
| BlackRock Extended Equity Market Fund | 6988 | -- | 6988 | -- | 2015-09-30 |
| Fidelity Spartan® Total Market Idx Fund | 19091 | 0.10% | -- | -- | 2015-09-30 |
| David F. Hale | Mr. David F. Hale is a Chairman at Adigica Health, Inc., a Chairman at Recros Medica, Inc., an Executive Chairman at MDRejuvena, Inc., a Chairman at Agility Clinical, Inc., a Non-Executive Chairman at Biocept, Inc., a Chairman at Advantar Laboratories, Inc., a Chairman at Conatus Pharmaceuticals, Inc., a Chairman at Hale BioPharma Ventures LLC, an Advisor at Windamere Venture Partners LLC, a Chairman at Clarify Medical, Inc., a Chairman at Intrepid Therapeutics, Inc., a Chairman at Oncternal Therapeutics, Inc., a Chairman at Rady Children's Institute for Genomic Medicine, a Chairman at Rich Diagnostics, Inc., a Chairman at Ridge Diagnostics, Inc., an Executive Chairman at Neurana Pharmaceuticals, Inc. and a General Partner at Hale Trading Co. LP. He is on the Board of Directors at Neurelis, Inc., BIOCOM, Dermata Therapeutics LLC, Idun Pharmaceuticals, Inc., San Diego Regional Economic Development Corp., Rady Children's Hospital & Health Center of San Diego and The Salk Institute for Biological Studies. |
|---|---|
| David T. Hagerty | David T. Hagerty is Executive Vice President-Clinical Development at Conatus Pharmaceuticals, Inc. In his past career Dr. Hagerty held the position of Chief Medical Officer & Senior Vice President for Ardea Biosciences, Inc., Executive Director-Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute and Vice President-Immunology & Rheumatology at Biogen Idec, Inc. (North Carolina). He received an undergraduate degree from the University of Notre Dame and a doctorate from Saint Louis University School of Medicine. |
| Daniel L. Kisner | Daniel L. Kisner is a businessperson who has been at the head of 7 different companies and currently holds the position of Chairman at Idun Pharmaceuticals, Inc. He is also on the board of 6 other companies. He previously was Chairman for Arbutus Biopharma Corp., Chairman for Caliper Technologies Corp., Chairman for Avera Pharmaceuticals, Inc., Chairman for Sequoia Pharmaceuticals, Inc., President & Chief Operating Officer for Ionis Pharmaceuticals, Inc., Partner at Aberdare Ventures, Vice President-Pharmaceutical Development at Abbott Laboratories, Chairman for Caliper Life Sciences, Inc. and Vice President-Clinical Research & Development at Smithkline Beckman Corp. Daniel L. Kisner received a doctorate from Georgetown University and an undergraduate degree from Rutgers State University of New Jersey. |
| William R. LaRue | Mr. William R. LaRue is an Independent Director at Conatus Pharmaceuticals, Inc. and an Independent Director at TRACON Pharmaceuticals, Inc. He is on the Board of Directors at Oncternal Therapeutics, Inc., Conatus Pharmaceuticals, Inc., Applied Proteomics, Inc., TRACON Pharmaceuticals, Inc. and ALASTIN Skincare, Inc. Mr. LaRue was previously employed as a CFO, Treasurer, Director & Senior VP by Cadence Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by Amgen Rockville, Inc., a Chief Financial Officer & Senior VP by CancerVax Corp., a Chief Financial Officer & Executive Vice President by eHelp Corp., a Treasurer & Vice President by Safeskin Corp., and a Treasurer by GDE Systems, Inc. He also served on the board at Oncternal Oncology, Inc. and Neurelis, Inc. He received his undergraduate degree from the University of Southern California and an MBA from the University of Southern California. |
| Harold E. van Wart | Harold E. van Wart is on the board of Idun Pharmaceuticals, Inc. and Conatus Pharmaceuticals, Inc. In his past career he was Chairman for California Biomedical Innovation Alliance and Chairman at The Bay Area Bioscience Association (a subsidiary of California Biomedical Innovation Alliance), President, Chief Executive Officer & Director at CymaBay Therapeutics, Inc., Vice President & Head-Therapy-Roche Bioscience at Syntex Corp. and Faculty Member at Florida State University. Harold E. van Wart received a doctorate from Cornell University and an undergraduate degree from State University of New York at Binghamton. |
| Steven J. Mento | Steven J. Mento founded Conatus Pharmaceuticals, Inc. Presently, he is President, Chief Executive Officer & Director at this company. Dr. Mento is also on the board of BIOCOM, BIO Emerging Co. and Donald P. Shiley Bioscience Center and Director & Member-Health Section at Biotechnology Innovation Organization. Dr. Mento previously held the position of Vice President-Research & Development of Viagene, Inc., Director-Viral Vaccine Research & Development at Lederle Praxis Biological, Inc., President, Chief Executive Officer & Director at Idun Pharmaceuticals, Inc., Vice President-Research & Development at Chiron Viagene, Inc., Vice President-Research & Development at Chiron Corp. and Assistant Research Professor at Icah School of Medicine at Mount Sinai. He received a doctorate, a graduate degree and an undergraduate degree from Rutgers State University of New Jersey. |
| Alfred P. Spada | Founder of Conatus Pharmaceuticals, Inc., Alfred P. Spada presently is CSO, Executive VP-Research & Development at this company. In the past Dr. Spada was Department Director at Aventis Pharmaceuticals, Inc., Department Director at Rhone Poulenc AG, Inc., Principal at Rorer Pharmaceuticals, Inc. and VP-Pharmaceutical & Preclinical Development at Idun Pharmaceuticals, Inc. Alfred P. Spada received an undergraduate degree from Worcester Polytechnic Institute and a doctorate from Massachusetts Institute of Technology. |
| Alan R. Engbring | Presently, Alan R. Engbring is Executive Director-IR & Communications at Conatus Pharmaceuticals, Inc. In the past Mr. Engbring occupied the position of Executive Director-Investor Relations at Vical, Inc. |
| Alfred P. Spada | Founder of Conatus Pharmaceuticals, Inc., Alfred P. Spada presently is CSO, Executive VP-Research & Development at this company. In the past Dr. Spada was Department Director at Aventis Pharmaceuticals, Inc., Department Director at Rhone Poulenc AG, Inc., Principal at Rorer Pharmaceuticals, Inc. and VP-Pharmaceutical & Preclinical Development at Idun Pharmaceuticals, Inc. Alfred P. Spada received an undergraduate degree from Worcester Polytechnic Institute and a doctorate from Massachusetts Institute of Technology. |
| Alan R. Engbring | Alan R. Engbring occupies the position of Executive Director-IR & Communications at Conatus Pharmaceuticals, Inc. In his past career Mr. Engbring held the position of Executive Director-Investor Relations at Vical, Inc. |
| Edward F. Smith | Edward F. Smith is Senior VP-Regulatory Affairs & Quality Assurance at Conatus Pharmaceuticals, Inc. In his past career Dr. Smith occupied the position of Vice President-Regulatory Affairs & Drug Safety at Zogenix, Inc., Director-Regulatory Affairs at Nektar Therapeutics, VP-Regulatory Affairs, Research & Development at Radiance Medical Systems, Inc., Principal at Mallinckrodt, Inc.(Old), Director-Corporate Regulatory Affairs at Valeant Pharmaceuticals International Corp., Principal at Smithkline Beecham Pharmaceuticals (India) Ltd., Senior Director-Regulatory Affairs at Stiefel Research Institute, Inc. and Senior Director-Regulatory Affairs at Connetics Corp. Edward F. Smith received a doctorate from Thomas Jefferson University, an undergraduate degree from Montana State University and an MBA from the University of Washington. |
| Preston S. Klassen | Presently, Preston S. Klassen holds the position of Chief Medical Officer, EVP-Research & Development at Arena Pharmaceuticals, Inc. and President at Sanifit, Inc. Dr. Klassen is also on the board of Conatus Pharmaceuticals, Inc. and Corvidia Therapeutics, Inc. In his past career he was President & Chief Medical Officer at Sanifit Therapeutics SA, Executive Director-Medical at Amgen, Inc. and Executive Vice President-Global Development at Orexigen Therapeutics, Inc. Dr. Klassen received a doctorate from the University of Nebraska Medical Center and a graduate degree from Duke University. |
| Daniel L. Ripley | Daniel L. Ripley is Senior VP-Business Development & Programme at Conatus Pharmaceuticals, Inc. In his past career Mr. Ripley occupied the position of Director-Business Development of Ionis Pharmaceuticals, Inc., Senior Director-Business Development at Kalypsys, Inc., Vice President-Business Development at BioBlocks, Inc., Director-Business Development for The Immune Response Corporation, Inc., Associate Director-Business Development at Orchestra Therapeutics, Inc. and Senior Director-Business Development at Apricus Biosciences, Inc. Mr. Ripley received an MBA and an undergraduate degree from San Diego State University. |
| Michelle L. Vandertie | Presently, Michelle L. Vandertie is Principal Accounting Officer & VP-Finance at Conatus Pharmaceuticals, Inc. Ms. Vandertie previously occupied the position of Corporate Controller at California Structures, Controller at Vical, Inc., Chief Financial Officer for Ajinomoto Althea, Inc. and Auditor at Ernst & Young LLP. Michelle L. Vandertie received an undergraduate degree from the University of Northern Colorado. |
| Keith W. Marshall | Founder of Montgomery, Marshall Healthcare Partners LLC, Keith W. Marshall presently is Executive VP, Chief Operating & Financial Officer at Conatus Pharmaceuticals, Inc. Dr. Marshall previously held the position of Chief Financial Officer & Managing Director at Montgomery, Marshall Healthcare Partners LLC, CFO & Head-Corporate Development at Torque Therapeutics, Inc., Managing Director-Healthcare Investment Ban at TAG Healthcare Advisors LLC, Research Associate at ImmuLogic Pharmaceutical Corp., Associate-Healthcare Investment Banking at JPMorgan H&Q Principals LP, Managing Director-Healthcare Investment Banking at GCA Savvian Advisors LLC, Managing Director-Healthcare Investment Banking at Montgomery & Co. and Managing Director at Sagent Advisors LLC. He received an MBA from The University of Chicago, a doctorate from the University of California and an undergraduate degree from the University of Washington. |
| Michael M. Mueller | Michael M. Mueller occupies the position of Secretary, Vice President & General Counsel for Conatus Pharmaceuticals, Inc. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论